Why the study?
Limb-girdle muscular dystrophy R1 has no available therapies, and whether induction of muscle growth via myostatin inhibition represents a viable therapeutic strategy was unknown.
Does myostatin inhibition improve muscle strength and exercise tolerance in a mouse model of limb-girdle muscular dystrophy R1?
Population
Mouse model of LGMD R1 (C3KO mice)
Comparison
Genetic (follistatin overexpression) or pharmacological (anti-myostatin antibody) myostatin inhibition vs control C3KO
Authors
Loading...
Myostatin inhibition unlikely to benefit LGMD R1; leaves open context-specific effects in other dystrophies.
Does myostatin inhibition improve muscle strength and exercise tolerance in a mouse model of limb-girdle muscular dystrophy R1?
Myostatin inhibition increases muscle mass but impairs oxidative capacity and exercise tolerance in a mouse model of LGMD R1, indicating it is unlikely to be a viable therapeutic strategy.
Kramerova et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: